About PanGenetics
PanGenetics is headquartered in Utrecht, The Netherlands with an office near Cambridge in the UK. The company specializes in taking antibodies at the late research stage through to clinical proof of concept. The company employs a lean business model with most development activities outsourced to specialist providers in Europe. The most advanced programs of PanGenetics are PG102, a CD40 antagonist that has already shown promise in an open label Crohn's study, and PG110, an anti-Nerve Growth Factor antibody for use in chronic pain. The company's management, board and advisors comprise many of the world's leading antibody developers.
- Focus : Manufacturer
- Industry : Pharma
Product portfolio of PanGenetics
Here you will find PanGenetics BV
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous